KURA ONCOLOGY VIRTUAL INVESTOR EVENT - KURA ONCOLOGY INC

Explicit Guidance:

• No specific financial guidance (revenue, earnings, margins, or timing of profitability) is provided for Cura Oncology or Caspian Therapeutics.
• The $50 million financing is allocated to support KO7246 through IND-enabling studies, initial clinical proof of concept, and the advancement of a second menin inhibitor candidate.
• Data disclosure timing is projected for "late 2028, possibly early 2029," following the planned initiation of first-in-human studies in Healthy Volunteers in 2028.
• Cura Oncology expects to provide a third-quarter earnings update at its next scheduled earnings call.

Business-Segment Outlook:

• Caspian Therapeutics: Established as a dedicated entity to advance KO7246 for Type 1 and Type 2 diabetes, with management retaining approximately 50% ownership of the new entity.
• KO7246 Development: Transitioning from preclinical (mouse, rat, human islet models) to IND-enabling studies to support the first clinical program.
• Pipeline Expansion: Caspian will simultaneously advance a second menin inhibitor candidate using the same strategic framework.
• Collaboration Structure: Cura Oncology will provide research, development, and corporate capabilities to Caspian via an intercompany services agreement while focusing internally on its oncology business.
• Proof of Concept (PoC) Definition: Success is defined by establishing a satisfactory safety/exposure profile and observing an increase in stimulated C-peptide (indicating improved endogenous insulin production) from baseline during or after treatment.

Market and Competitive Outlook:

• Target Mechanism: KO7246 targets a unique mechanism: the selective proliferation of beta cells to restore endogenous insulin capacity, distinguishing it from existing glucose-lowering agents.
• Competitive Positioning: KO7246 is positioned as complementary to current standard of care, specifically GLP-1 receptor agonists, with potential synergy due to shared goals of enhancing beta cell function and number.
• Differentiation vs. Competitors:
  • KO7246 is reported to be ~3x more potent than balameb (formerly KO7246) in vitro and demonstrates superior activity at lower doses.
  • KO7246 is distinguished from icovamenib (ICOBAMEN/BMF219) by its specific menin-MLL inhibition; ICOVAMENIB showed no efficacy in menin-dependent models and displayed off-target kinase inhibition (CDK9, etc.).
• Market Need: Addresses the unmet need for therapies that restore physiologic insulin response rather than merely lowering glucose, with a focus on patients with residual beta cell mass.

Macro / Industry Outlook:

• Clinical Strategy: Management anticipates a "therapeutic window" allows for chronic or intermittent dosing, though the specific paradigm (continuous vs. fixed course) requires human data to define.
• Safety Profile: Anticipated safety profile is favorable for chronic metabolic use compared to oncology indications, citing the lack of on-target toxicities observed in long-term AML trials (e.g., no liver toxicity associated with pure menin inhibition).
• Regulatory/Development Path: The company plans to validate the mechanism through first-in-human studies in Healthy Volunteers before progressing to patient trials.

Strategic Initiatives:

• Corporate Spinout: Creation of Caspian Therapeutics to isolate diabetes development efforts, funded by a $50M round led by BDF Partners, T1D Fund, Eli Lilly, and others.
• Molecule Optimization: KO7246 was specifically designed with a higher tolerability bar for chronic metabolic disease than oncology, featuring:
  • No interaction with the CYP system or hERG channel.
  • Comprehensive GLP-grade gene toxicity screening showing a clean profile.
  • Oral, once-daily dosing regimen designed to clear between doses.
• Future Indications: The teams are evaluating other potential metabolic indications beyond T1D and T2D, leveraging menin's role in epigenetic regulation and beta cell biology.

Risks and Headwinds to Outlook:

• Patient Selection Sensitivity: The binary response (complete recovery vs. no response) in preclinical models suggests a strict threshold of residual beta cell mass is required; patients with very low C-peptide may not respond.
• Response Variability: The speed of beta cell regeneration in humans is uncertain and expected to vary based on baseline islet mass, potentially leading to different response times compared to rodents.
• Autoimmunity in T1D: The therapy does not address the underlying autoimmune destruction; success may require combination therapies to "tamp down" autoimmunity in Type 1 patients.
• Competitor Safety Concerns: The transcript references another menin inhibitor reporting liver toxicity and off-target effects, highlighting the risk of class-specific safety issues if non-selective agents are used.
• Data Disclosure Limitations: Specific data from first-in-human studies and detailed trial designs may not be fully disclosed until later stages.

Management Tone on the Future:

• Confidence Level: High confidence in the scientific basis of menin inhibition for beta cell regeneration, citing consistent efficacy across mouse, rat, and human islet models.
• Cautious Optimism on Human Translation: While preclinical data is robust, management emphasizes the need to validate the "sliding doors" threshold of beta cell mass and the exact dosing paradigm in humans before expecting meaningful patient benefits.
• Strategic Clarity: Expresses clarity in separating the diabetes asset (Caspian) from the oncology core (Cura) to ensure dedicated focus and capital alignment, viewing this as a unique opportunity for investors to participate in beta cell regeneration.

Miscellaneous:

• Ownership Structure: Cura Oncology retains ~50% of Caspian, providing shareholders exposure to the diabetes upside.
• Investor Base: New financing includes participation from strategic partners Eli Lilly & Company and the T1D Fund.
• Comparison to Ziftimenib: Management notes that menin inhibitors have been used safely in AML patients for years without obvious metabolic toxicity, providing reassurance for chronic use in diabetes.
• Non-Responder Analysis: Preclinical non-responders were correlated with high baseline fasting blood glucose (indicating low initial beta cell pool), reinforcing the need for specific patient stratification.